Trials / Active Not Recruiting
Active Not RecruitingNCT07229157
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maridebart Cafraglutide | Participants will receive maridebart cafraglutide SC. |
| DRUG | Moxifloxacin | Participants will receive moxifloxacin orally. |
| DRUG | Placebo for Maridebart Cafraglutide | Participants will receive placebo for maridebart cafraglutide SC. |
| DRUG | Placebo for Moxifloxacin | Participants will receive placebo for moxifloxacin orally. |
Timeline
- Start date
- 2025-10-22
- Primary completion
- 2026-08-26
- Completion
- 2026-08-26
- First posted
- 2025-11-14
- Last updated
- 2026-01-23
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07229157. Inclusion in this directory is not an endorsement.